 |
|
Head and Neck Cancer Trial Results
1. HPV Status Can Predict Outcome in Oropharyngeal Cancer
(Posted: 06/19/2009) - Patients with advanced oropharyngeal cancer are more likely to survive if their tumors are HPV positive than if they are HPV negative, according to findings presented at the 2009 ASCO meeting in Orlando.
2. Cetuximab (Erbitux®) Plus Chemo Extends Survival in Advanced Head and Neck Cancer
(Posted: 06/26/2007, Reviewed: 09/16/2008) - Patients with recurrent or metastatic squamous cell carcinoma of the head and neck who received cetuximab (Erbitux®) in addition to standard chemotherapy lived about three months longer than those receiving chemotherapy alone, according to findings presented at the 2007 ASCO meeting in Chicago.
3. Chemotherapy During Radiation Treatment Improves Outcomes in Nasopharyngeal Cancer
(Posted: 02/15/2006) - In this meta-analysis, researchers found that chemotherapy given during standard radiation treatment for nasopharyngeal cancer reduced the risk of death, and also of cancer recurrence, according to the Jan. 1, 2006, issue of the International Journal of Radiation Oncology, Biology, Physics.
4. Cetuximab (Erbitux®) Plus Radiation Beneficial for Patients with Head and Neck Cancer
(Posted: 06/05/2004, Updated: 02/13/2006) - Compared to radiation alone, cetuximab plus radiation therapy can nearly double the median survival in patients with a certain kind of head and neck cancer that has not spread to other parts of the body, according to the Feb. 9, 2006, issue of the New England Journal of Medicine.
5. Oxaliplatin (Eloxatin®) Plus Radiation Superior in Advanced Nasopharyngeal Cancer
(Posted: 11/02/2005) - Patients with locally advanced nasopharyngeal cancer who received oxaliplatin (Eloxatin®) during their initial treatment with radiotherapy did significantly better than those receiving radiation alone, according to a report published online Oct. 17, 2005, by the Journal of Clinical Oncology.
1 2 Next >
|
|
|
